These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9704617)

  • 1. Monitoring heparin therapy: APTT results from partial- vs full-draw tubes.
    Siegel JE; Bernard DW; Swami VK; Sazama K
    Am J Clin Pathol; 1998 Aug; 110(2):184-7. PubMed ID: 9704617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.
    Heyns AD; van den Berg DJ; Kleynhans PH; du Toit PW
    J Clin Pathol; 1981 Jan; 34(1):63-8. PubMed ID: 7462439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
    Marlar RA; Clement B; Gausman J
    Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underestimation of unfractionated heparin therapy assessment due to platelet activation when using partial-draw (pediatric) citrate collection tubes.
    Desconclois C; Eschwège V; Proulle V; Boutekedjiret T; Dreyfus M; Toulon P
    Thromb Res; 2014 Nov; 134(5):1117-22. PubMed ID: 25248688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S; Preston FE
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new plastic collection tube made of polyethylene terephtalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractionated heparin, and low molecular weight heparin).
    Toulon P; Ajzenberg N; Smahi M; Guillin MC
    Thromb Res; 2007; 119(2):135-43. PubMed ID: 16426667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring unfractionated heparin with the aPTT: time for a fresh look.
    Eikelboom JW; Hirsh J
    Thromb Haemost; 2006 Nov; 96(5):547-52. PubMed ID: 17080209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW; Vondracek TG
    Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range.
    Marlar RA; Gausman JN
    Int J Lab Hematol; 2012 Dec; 34(6):614-20. PubMed ID: 22712447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation.
    Thompson MH; Wilson SH; Toussaint BL; Jordan CL; Hayes GL; McKinzie BP; Wolf BJ; Field LC
    J Clin Anesth; 2016 Sep; 33():346-50. PubMed ID: 27555191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring.
    Taylor CT; Petros WP; Ortel TL
    Pharmacotherapy; 1999 Apr; 19(4):383-7. PubMed ID: 10212007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
    Kershaw G
    Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring unfractionated heparin therapy. 4 hour-stability of anti-Xa activity in unspun citrated tubes.
    Toulon P; Appert-Flory A; Fischer F; Buvat S; Jambou D; Mahagne MH
    Thromb Res; 2020 Feb; 186():7-12. PubMed ID: 31837560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy.
    Gausman JN; Marlar RA
    Am J Clin Pathol; 2011 Jun; 135(6):870-6. PubMed ID: 21571960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing an institution-specific therapeutic range for heparin.
    Volles DF; Ancell CJ; Michael KA; Mullins DM; Humphries JE
    Am J Health Syst Pharm; 1998 Oct; 55(19):2002-6. PubMed ID: 9784787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The accuracy of a point of care measurement of activated partial thromboplastin time in intensive care patients.
    Karigowda L; Deshpande K; Jones S; Miller J
    Pathology; 2019 Oct; 51(6):628-633. PubMed ID: 31445807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin.
    Simko RJ; Tsung FF; Stanek EJ
    Ann Pharmacother; 1995 Oct; 29(10):1015-21; quiz 1061. PubMed ID: 8845539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between siliconized evacuated glass and plastic blood collection tubes for prothrombin time and activated partial thromboplastin time assay in normal patients, patients on oral anticoagulant therapy and patients with unfractioned heparin therapy.
    D'Angelo G; Villa C
    Int J Lab Hematol; 2011 Apr; 33(2):219-25. PubMed ID: 20979595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.